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Short Communication
Non interference by heparin with the cytostatic effect of
Adriamycin: An in vitro study on a human promyelocytic
leukaemia cell line
P. Foa, E. Cofrancesco, L. Lombardi, M. Colombi, E.M. Pogliani & E.E. Polli
First Institute ofClinical Medicine, University ofMilan, Italy.
Adriamycin, a widely used powerful antitumour
agent, has been reported to interact in vitro with
heparin, with formation of an ionic complex
(Menozzi & Arcamone, 1978). Since adriamycin
and heparin are often associated in the treatment of
solid tumours and acute leukaemias (Cliffton &
Grossi, 1974; Donati & Poggi, 1980), we
investigated whether such an interaction would
interfere with the pharmacological effect of the
drugs. While it has been shown in both in vitro and
in vivo experiments that adriamycin neutralizes the
anticoagulant activity of heparin (Cofrancesco et
al., 1980), conflicting results on inhibition by
heparin of the cytostatic activity of adriamycin
have been reported. While in an animal model
(Lewis lung carcinoma in mice) heparin did not
interfere with the anticancer activity of adriamycin
(Colombo et al., 1981) the opposite effect was
recorded in an in vitro system consisting of human
PHA-stimulated lymphocytes (Muntean et al.,
1981).
Because of the obvious clinical relevance of this
problem, we have conducted further investigations
using an in vitro continuous human promyelocytic
leukaemia cell line HL60 (Collins et al., 1977).
Such an experimental model was selected because
human promyelocytic leukaemia is typically treated
with simultaneous administration of anthracyclines
and heparin and because the evaluation of a
possible inhibition by heparin of anthracycline
activity could hardly be performed in a prospective
clinical trial.
The HL60 cell line established from a patient
with an acute promyelocytic leukaemia (Collins et
al., 1977), was propagated in RPMI 1640 medium
(Gibco) supplemented with 20% foetal calf serum
(Gibco); cultures were maintained at 37°C in a humi-
dified 5% CO2 atmosphere. The single drugs and the
heparin-adriamycin complex (see below) were added
at the beginning of each experiment to 1 ml cultures
containing 106 HL60 cells ml-1, and the cytostatic
effect was assessed in terms of reduction of [3H]-
thymidine ([3H]-dT) incorporation into insoluble
DNA. For that purpose 180min after the beginning
of each experiment, [3H]-dT (The Radiochemical
Centre, Amersham, Sp.act. 25CimM-1, was
added to the cultures at a final concentration of
1 CCmF 1, and, after an additional 60min
incubation, [3H]-dT incorporation into insoluble
DNA was measured by means of a filter paper
technique (Blazsek & Gall, 1978). Cell viability was
also assessed according to the dye exclusion
method, by incubation of the cell samples with a
trypan blue solution for 30min at 37°C.
In order to assess the heparin anticoagulant
activity, at the end of each experiment the
supernatant from aliquots of HL60 cultures was
collected after 10min centrifugation at 400g. For
the same purpose the pellet was sonicated for 20sec
at 200W (Branson Cell Sonifier), and resuspended in
phenol red-free Hanks balanced salt solution
(HBSS).
Heparin sodium salt (Liquemin, Roche) and
adriamycin hydrochloride (Farmitalia-Carlo Erba)
were diluted separately in sterile phenol red-free
HBSS. In order to allow optimal interaction
between the drugs, heparin and adriamycin were
preincubated together at 37°C for 30min before
being added to the cultures.
In a first set of experiments, 10gml-1
adriamycin was preincubated with increasing
heparin concentrations from 0.08 to 3.2I.U.ml'
and then added to HL60 cultures so that the final
adriamycin concentration was 2ygmi-1. In a
second set of experiments 5pgml-1 adriamycin was
preincubated with the previous heparin
concentrations and then added to HL60 cultures so
that the final adriamycin concentration was
lpgmi-1.
©) The Macmillan Press Ltd., 1983
Correspondence: P. Foa, Istituto Clinica Medica I,
Universita di Milano, Via F. Sforza, 35-1-20122 Milano,
Italy.
Received 22 February 1983; Accepted 14 July 1983.736 P. FOA et al.
For assessment of heparin anticoagulant activity
platelet-poor plasma (PPP) was obtained by
centrifuging for 10min at 3,000g 100ml of freshly
collected citrated (1:10) blood pooled from 10
healthy human donors (5 male and 5 female).
Purified antithrombin III was obtained from Kabi
(Stockholm, Sweden). The dried preparation was
dissolved in saline at a concentration of 1 Uml-'.
The effect of the heparin-adriamycin interaction on
the anticoagulant activity of heparin was studied by
an amidolytic method (Teien & Lie, 1977), using
S2222 as a substrate (COATEST Heparin, Ortho
Diagnostic, Milan, Italy). For that purpose a
solution containing 100 lp of PPP and 700,p of
Tris-EDTA buffer was prepared. Two hundred pl of
this solution was warmed for 4min at 37°C and
then 100lpI of factor X (7nkatml-1) was added.
Thirty seconds later for heparin concentrations
from 0.1 to 0.7I.U.ml- 1 and 180 sec later for
heparin concentrations from 0.02 to 0.15I.U.ml-1,
200jp1 of S2222 (1 mM 1-) was added. After 3min
the reaction was stopped by adding 300p1 of 50%
acetic acid, and the absorbance at 405nm was read.
The tests were run in quadruplicate at least 3 times.
The difference between the activities measured in
the same sample never exceeded 10%.
In each experiment an analysis of variance was
performed according to a factorial scheme where
the sources of variability was represented by each of
the two selected adriamycin concentrations, by
heparin concentrations and by their interactions.
As a preliminary step, we assessed the effect of
adriamycin on [3H]-dT uptake by HL60 cells. A
dose-related inhibition of the isotope incorporation
was recorded over a wide range of drug
concentrations (Figure 1). Cell viability, which was
also assessed, was not affected even by the highest
drug concentration (2pgml-1).
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Figure 1 Effect of different adriamycin conc
on [3H]-dT uptake by HL60 cells. Ea
represents the mean +s.d. of 4 independent c
The effect of heparin on [3H]-dT uptake was also
investigated. A wide range of concentrations (0.04-
8 I.U.ml-1) encompassing the therapeutic doses was
evaluated; no statistically significant effect was
found, nor could any effect on cell viability be
detected (date not shown). In order to assess the
effect of heparin on adriamycin's cytostatic activity,
10 ugml-1 adriamycin was preincubated with
increasing concentrations of heparin. As shown in
Figure 2 (lower part), inhibition of [3H]-dT uptake
by adriamycin was not significantly affected even by
the highest heparin concentration used. In order to
reduce a possible excess of adriamycin during the
preincubation phase, in a further set of experiments
a halved concentration of this drug (5pgml-1) was
incubated with unchanged concentrations of
heparin, but the cytostatic effect of adriamycin was
not reversed even by the highest heparin
concentration (Figure 2 upper part). Cell viability,
which was assessed in each experiment, was not
affected by the heparin-adriamycin complex.
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Figure 2 Effect of 30min preincubation with
increasing heparin concentrations on the inhibition of
[3H]-dT uptake in HL60 cells by 2 concentrations of
adriamycin. Each point represents the mean +s.d. of 4
independent cultures. (0) Final adriamycin
concentration in HL60 cultures, 2pgml-'. (0) Final
adriamycin concentrations in HL60 cultures,
1mgml-'.
~^i In all experiments, the effect of adriamycin on the
anticoagulant activity of heparin was assessed after
30min preincubation without cells and also after 4h
culture of the complex with HL60 cells in which
^ 2 case the heparin activity was measured both in the
culture supernatant and in sonicated cells. The
results of a typical experiment where the adriamycin
centrations concentration during the preincubation period was
ach point 10pgml-1 are shown in Table I. At the end of
cultures. 30min preincubation the complexation of the two
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Table I Heparin activity (I.U.ml- 1) at the various times in a typical experiment.
In the supernatant after In sonicated cells after
After 30min incubation 4h incubation ofthe 4h incubation ofthe
In the initial ofheparin solutions heparin adriamycin complex heparin adriamycin
heparin solutions with lOigmli' adriamycin with HL60 cells complex with H160 cells
0.040 0.020 0.030 0.010
0.080 0.032 0.045 0.040
0.160 0.060 0.075 0.080
0.320 0.140 0.160 0.150
drugs was optimal, and the anticoagulant activity of
heparin was greatly reduced (column II), no further
reduction of its biological activity was observed by
extending the incubation time to 4h and no
significant difference in heparin levels was found
when the incubation proceeded in saline or in the
culture medium. After 4h incubation of the complex
with the cell suspension, the heparin activity was
measured both in the supernatant of the cell
suspension (column III) and in the sonicated cells
(column IV).
It is noteworthy that the sum of these two values
(column III+column IV) gives exactly the initial
value (column I). The same pattern of results was
also found in those experiments where the
adriamycin concentration during the preincubation
period was 5 ugml-1.
Heparin alone, at the concentrations given in
Table I, was also incubated for 4h with HL60 cells.
After such incubations, all the heparin activity was
recovered in the supernatant, while no activity
could be detected in sonicated cells, thus suggesting
that the drug alone does not enter HL60 cells.
It has been shown that heparin and adriamycin
can interact in vitro with formation of an ionic
complex and that such binding reduces the
anticoagulant activity of heparin (Cofrancesco et al.,
1980). From the clinical point of view, it is even
more important to clarify also whether the
cytostatic activity of adriamycin is affected by
heparin, since the drugs are often given
simultaneously to cancer patients. However, the
reports published so far are conflicting. According
to an in vivo study, the anticancer effect of
adriamycin in mice with the Lewis lung carcinoma
was not affected by simultaneous administration of
heparin (Colombo et al., 1981). Since the
adriamycin uptake by target cells is very rapid
(T 1/2=2-3min) it could be speculated that in such
an in vivo study adriamycin might have largely
disappeared from the blood before optimal binding
with heparin. Aware of this criticism, in the present
study performed on a human continuous
promyelocytic leukaemic cell line, adriamycin and
heparin were preincubated together for 30min
before biological testing, so as to allow optimal
interaction between the drugs to take place.
According to our data, the cytostatic activity of
adriamycin was not altered by preincubation with a
wide range of heparin concentrations including
therapeutic doses.
Our data do not concur with a previous report
(Muntean et al., 1981) stating that the cytostatic
effect ofadriamycin on PHA-stimulated lymphocytes
was inhibited by the simultaneous administration of
heparin. However, the latter experimental system
might not be an ideal one since the proliferation of
PHA-stimulated lymphocytes is not spontaneous
but triggered by an exogenous agent which, at least
in theory, might interfere with the drugs to be
assayed by the experimental system.
While the main results of our study show that the
cytostatic activity of adriamycin is not modified by
interaction with heparin, the data on the
anticoagulant activity of heparin aiso deserve some
comment. Our findings on the biological activity of
heparin confirm what was already known on the
interaction of this drug with adriamycin in a cell-
free system. In addition, after 4h incubation of the
drugs complex with HL60 cells at 37°C, we found
anticoagulant activity in both the supernatant of
the cell cultures (this value probably corresponds to
the unbound fraction of heparin) and the sonicated
cells. A tentative explanation of such a finding is
that the adriamycin-heparin complex can traverse
the cell membrane whence it is cleared within the
cells and the heparin recovers entirely its
anticoagulant activity.
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